User-friendly, waterproof§ design
Remote insulin dosing
Insulin pump therapy with the MiniMed system makes it easier to stay in range. With our pump and sensor system, you’re four times more likely to reach your target A1C.2 You can also reduce low glucose episodes by up to 84 percent and lower the risk of long-term complications.3,4
reduced up to 54%4
reduced up to 41%4
reduced up to 41%4
reduced up to 53%4
Want to be first in line for the new system?
Purchase a MiniMed 630G system today, and get the MiniMed 670G system for just $799 when it becomes available. Experience our newest pump platform now for a smooth transition to the MiniMed 670G system, available in spring of 2017.
As a valued customer, you have the option to bring your total out-of-pocket cost down to only $299 when you send back your MiniMed 630G pump and transmitter for a $500 exchange credit.
Limited time offer: Your final cost for the MiniMed 670G system could be as low as $0†† if you participate in an approved system access program.
Take the next step by filling out the form.
To speak with a Diabetes Therapy
For more information, please fill out the form or call 1-877-874-6120. Be sure to ask about a free insurance check. If you are a new customer, you may qualify for our free six-week product trial5. Click here
If you have the new MiniMed 630G system, we've got the skins, pouches, cases and clips to help you make it your own.
* CGM uses a special sensor to measure sugar levels just below the skin known as interstitial fluid. These sensor glucose (SG) values are different from blood glucose (BG) measurements using a BG meter. Sensor glucose values should not be used to make treatment decisions. Patients should always do a BG fingerstick before they make treatment decisions.
** The Bolus Wizard calculator does not account for manual injections and could prompt you to deliver more insulin than needed. Too much insulin may cause hypoglycemia. Consult with your healthcare professional for how long you need to wait after a manual injection before you can rely on the active insulin calculation of your Bolus Wizard calculator.
† When calibrating three to four times a day and predictive and low alerts are both turned on. There may be times falling within a range approved by the FDA when the system may falsely alert (i.e., alerts when blood glucose levels are above the alert setting).
†† For a limited time until April 28, 2017, your Priority Access program out-of-pocket cost could go as low as $0 if you purchase a MiniMed® 630G system and participate in an approved system access program. Additional terms and restrictions may apply.
‡ Enlite Sensor Performance Clinical Appendix.
§ The pump is protected against the effects of continuous immersion in up to 12 feet (3.6 meters) of water for up to 24 hours at a time at the time of manufacture. This is classified as IPX8 rating. See user guide for more details.
¶ Assumes four injections per day for 30 days and one infusion set change every three days.
1. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomized controlled trial. Diabetologia. 2012;55:3155–3162. 2. Doyle EA, Weinzimer SA, Steffen AT, Ahern JAH, Vincent M, Tamborlane WV. A randomized prospective trial comparing the efficacy of insulin pump therapy with multiple daily injections using insulin glargine. Diabetes Care. 2004;27(7):1554–1558. 3. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in Type 1 diabetes. Diabetes Care. 1996;19:324–327. 4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. 5. The Pump Trial Program is available to new customers only. To enroll in the six-week free product trial you must be insulin-dependent, must complete insurance verification, and must have a prescription on file. You must sign a legal agreement acknowledging that you will return the product used during the trial within 30 days of the end of the trial if you decide not to continue with pump therapy. You must commit to uploading into CareLink© Personal 3 times (once every two weeks throughout product trial). 6. Bailey T, et al. Accuracy, Precision, and User Performance Evaluation of the CONTOUR®NEXT LINK 2.4 Blood Glucose Monitoring System. Poster presented at the 7th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD); 2014 February 5–8, Vienna, Austria.
The MiniMed 630G system with SmartGuard™ technology requires a prescription. It is intended for continuous delivery of basal insulin and administration of insulin boluses for the management of diabetes mellitus in persons 16 years of age or older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The SmartGuard feature allows one to program the pump to temporarily suspend delivery of insulin for up to two hours when the sensor glucose value falls below a predefined threshold value. The MiniMed 630G system is not intended to be used directly for making therapy adjustments or preventing or treating hypoglycemia. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare professional. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter (BGM). A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 Meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. Do not calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always’ send mode. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day, or who are unwilling or unable to maintain contact with their healthcare professional, or whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use U100 rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. WARNING: The SmartGuard Suspend on low feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set limit. Under some conditions of use the pump can suspend again resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard Suspend on low feature, it is important to read the SmartGuard Suspend on low information in the Getting Started Guide and the MiniMed 630G System User Guide and discuss proper use of the SmartGuard Suspend on low feature with your healthcare professional.
Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected.
The Medtronic MiniMed 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G system includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site (palm) or from a control solution test. Do not calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. WARNING: Medtronic performed an evaluation of the MiniMed 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely. Only use rapid acting U100 insulin with this system. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed 670G system has not been studied in pregnant women. For complete details, including product and important safety information concerning the system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library.
Go to medtronicdiabetes.com/importantsafetyinformation to review the important safety information.
MiniMed, Enlite, CareLink, Bolus Wizard and Guardian are registered trademarks, SmartGuard is a trademark and StartRight is a service mark of Medtronic MiniMed, Inc.
Ascensia and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care. The Bayer Cross is a registered trademark of Bayer. MiniMed is a trademark of Medtronic MiniMed, Inc. © 2016 Medtronic MiniMed, Inc. All rights reserved. 940M14212-011 20151030
Individuals portrayed are not actual customers.